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Abstract
Aim: To review current literature on long-chain alcohols and their derivatives as novel pharmacotherapy for the treatment of essential tremor (ET).
Background: Currently available and recommended pharmacotherapies for ET are often limited by suboptimal treatment effects, frequent adverse effects, and
drug interactions. While ethanol is reported to profoundly decrease tremor severity in the majority of patients with ET, preclinical experience suggests that long-
chain alcohols such as 1-octanol might lead to a comparable tremor reduction without ethanol’s typical side effects of sedation and intoxication. Here, we review the
literature on the first clinical trials on 1-octanol and its metabolite octanoic acid (OA) for the treatment of ET.
Methods: The literature on preclinical and clinical trials on long-chain alcohols as well as OA was reviewed and summarized, and an outlook given on next phases
of development.
Discussion: 1-octanol was demonstrated to be safe and effective in a double-blind, placebo-controlled low-dose trial, and open-label data showed excellent
tolerability and dose-dependent efficacy up to 128 mg/kg. Despite 1-octanol’s efficacy, its future viability as an effective therapy is limited by its pharmacological
properties that require large volumes to be orally administered. Pharmacokinetic data indicate that OA is the active metabolite of 1-octanol. Preclinical efficacy data
for OA are positive, and human pilot data demonstrated excellent safety as well as efficacy in secondary outcome measures of tremor amplitudes. OA also has more
favorable pharmacological properties for drug delivery; hence, OA may be worth developing as a pharmaceutical.
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Introduction
Essential tremor (ET) is a common movement disorder with a
prevalence in the general population between 0.4% and 3.9%.1 ET is a
slowly progressive disease with 73% of patients describing disabilities
in multiple functional domains including eating, drinking, writing, and
body care.2
Since there is currently no curative therapy available for ET,
medical agents including propranolol and primidone as well as deep
brain stimulation of the ventral intermediate nucleus (VIM) are
symptomatic therapeutic options. However, the clinical effects of these
first-line drugs are often limited by contraindications and intolerable
side effects, particularly in elderly patients,3 and many patients are not
keen on surgery.
Ethanol and essential tremor
One characteristic observation in ET is that up to 74% of affected
subjects report a significant reduction in tremor intensity after the
administration of small amounts of ethanol.4–6 It should be noted that
this observation is based on subjective data only, while objective data
on the ethanol response in ET is scarce. In a study by Knudsen et al.,7
a standardized oral ethanol challenge led to an improvement of up to
50% of hand tremor scores in 25 patients, which lasted up to 3 h. It
was also demonstrated by the same group that after ethanol, ataxia
scores and number of missteps during tandem gait improved equally in
patients with ET, suggesting a beneficial effect of ethanol in ET
patients beyond the actual tremor.8 The evidence for a central effect of
ethanol stems from neurophysiological studies using weighted accel-
erometry demonstrating a significant reduction of the central tremor
component following standardized oral ethanol administration.9
Furthermore, the specificity of the effect was demonstrated to be
mediated by the central nervous system (CNS), as an effect was seen
after systemic intravenous administration, without effect after intra-
arterial perfusion in a vascularly isolated limb of patients with ET.10
The tremor-reducing effect on the central component was demon-
strated to be specific for ethanol, as diazepam showed no effect.
Furthermore, this finding demonstrated that ethanol acted specifically
on a central tremor oscillator at plasma ethanol levels of 0.05 g/dL,
independent of effects mediated through relaxation or sedation seen
with diazepam.9
Several hypotheses exist regarding the mechanism of ethanol’s effect
in ET.
First, ethanol has been suggested to decrease the neuronal firing rate
of the inferior olive (IO) and may therefore lead to a reduction in
hypersynchronous bursting activity within Mollaret’s triangle connect-
ing the red nucleus, the IO, and the cerebellum, with further
propagation along the cerebello-thalamo-cortical loop.11 There are
two possible derangements. First, this mechanism is thought to be
mediated through modulation of low-threshold calcium channels in
the IO that are responsible for rhythmical cellular firing.
There can be hyperfunctioning of the low-threshold calcium
channel in the inferior olivary cells leading to oscillatory neuronal
activity.12 Notably, ethanol in low doses has been reported to increase
T-type currents of low-threshold calcium channels; however, at toxic
levels data show ethanol is blocking these channels.13 While the
relevance of low-threshold calcium channels has been demonstrated in
the harmaline model of ET, the role in humans remains to be
elucidated, as in humans lesions affecting the efferent cerebellar
pathways (such as strokes) might abolish tremor in ET patients, but no
‘‘curative’’ lesions affecting the IO complex have been reported so
far.14
Contrary to the hypothesis of ethanol as a depressor of neuronal IO
firing, a study using different methods of anesthesia by Rogers et al.15
suggested that the depressing effect might in fact be due to the specific
anesthesia used in the original experiment by Harris and Sinclair
(urethane),11 as ethanol under this varying anesthesia condition
actually led to an increase in the IO single-unit firing rate.
Second, the neuronal rhythmic discharges within the IO may be
hypersynchronized by electrical coupling mediated through gap
junctions.16 These gap junctions connect and therefore electrically
couple dendritic spines in synaptic glomeruli within the IO, which are
thought to be central for the IO’s oscillatory activity. Gamma-
aminobutyric acid (GABA)ergic terminals in the synaptic glomeruli
have shown to decrease the extent of electric coupling.17 By blocking
connexin 36, a crucial gap junction protein within the IO, mice still
develop harmaline-induced tremor although with decreased tremor
coherence.18,19 This suggests that the profound tremor-reducing effect
of gap junction blockers such as mefloquine in harmaline mice may act
via different gap junctions, not containing connexin 36.20
Furthermore, ethanol’s agonism on GABA-receptors has been
implicated as a correlate of its tremor-suppressing properties. GABA is
the main inhibitory neurotransmitter, with GABAA receptors being
expressed either synaptically (90%) or extrasynaptically (10%).
Synaptic receptors mediate phasic inhibition, whereas tonic inhibition
is mediated via extrasynaptic receptors,21 which are thought be
physiologically activated by ‘‘overspill’’ of synaptically released
GABA.22 GABAA receptors form pentamers containing two alpha,
two beta, and either one gamma or one delta subunit.23 The majority
of GABAA receptors contain a gamma subunit, are expressed
synaptically, and are benzodiazepine sensitive. Receptors containing
a delta subunit are mainly expressed extrasynaptically and are non-
sensitive to benzodiazepines but in contrast show a very high sensitivity
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to GABA and ethanol, and therefore might play a role in facilitating a
GABAergic effect of ethanol.24 Delta subunits containing receptors
form pentamers with alpha1, 4, and 6 subunits. While alpha1delta
receptors can only be found in the hippocampus, alpha6delta receptors
are exclusively expressed in cerebellar granule cells, and alpha4delta
receptors more widespread in the cerebral cortex, thalamus, and the
cerebellum.25 The major role of the extrasynaptically located
alpha6delta receptor in determining the response to ethanol has been
confirmed in a recombinant study where the R100Q polymorphism of
the gene coding for the alpha6 subunit was shown to enhance
sensitivity to ethanol.26 While alpha1 subunit knockout mice have been
suggested to exhibit a phenotype resembling ET including ethanol
responsivity, a screen for variants in the gene coding for the alpha1
subunit showed no genetic differences between ET subjects and
controls.27,28 Genetic alpha6 subunit variants have been associated
with different levels of response to ethanol in humans.29
Although disputed by others,30 data from a prospective ET brain
bank study showed a reduced cerebellar Purkinje cell number in over
75% of patients compared with control brains.31 With GABA being
the main neurotransmitter of Purkinje cell projections, ET has been
suggested to be a ‘‘Purkinjopathy’’, also characterized by increased
prevalence of axonal swellings (‘‘torpedoes’’) of Purkinje neurons in ET
brains.32,33
Summarizing the evidence on the ethanol effect in ET, although there
are several hypotheses on the potential mechanisms of action, it is
important to point out that insights gained from the harmaline model
are not certain to reflect the human pathophysiologic mechanism in ET.
Specifically, T-type calcium channels and non-connexin 36 gap
junctions in CNS regions other than the IO, as well as the
GABAergic system, represent relevant targets to be further investigated.
Methods
The relevant literature on preclinical and clinical trials of long-chain
alcohols and OA were identified via a Pubmed search. Search terms
were ‘‘octanol’’, ‘‘1-octanol’’, ‘‘octanoic acid’’, and ‘‘caprylic acid’’,
with searches limited to clinical trials. Furthermore, the terms
‘‘ethanol’’ and ‘‘alcohol’’ were searched in conjunction with ‘‘essential
tremor’’. The time frame of papers to be included was limited by the
time point of the writing of this manuscript (October 2013). Because of
limited relevance to this review, trials involving octanoic acid as a 13C-
labeled substance to investigate gastric emptying were excluded from
the search. Secondary literature was followed up, reviewed, and
discussed here if found relevant to the topic of this manuscript. Here
we provide a summary of the review as well as an outlook given on the
next phases of development.
Results and discussion
Long-chain alcohols
Alcohols ranging from methanol (CH4O) to decanol (C10H22O)
were first studied using an in vitro model of guinea-pig IO neurons,
where octanol was described to be a potent antagonist of IO low-
threshold calcium channels.34 In a further step, several octanol
isomers, including 1-octanol, were first studied in vivo using the
harmaline-induced rodent model of ET. All isomers, at varying
effective doses, demonstrated a potent effect in reducing harmaline-
induced tremor.35 In a comparative study on 1-octanol and 1-
heptanol, both long-chain alcohols, reduced harmaline-induced
tremor in mice at a dose of 350 mg/kg after intraperitoneal
administration, with 1-octanol exhibiting a superior efficacy profile
than 1-heptanol due to a longer duration of the effect.20
1-Octanol: preclinical evidence
The eight-chain alcohol 1-octanol is hypothesized to be metabolized
by octanol dehydrogenase, a member of the alcohol dehydrogenase
family of enzymes, to an aldehyde and then a carboxylic acid that is
either oxidized completely to carbon dioxide and water or excreted as
an ether-glucuronide after direct conjugation with glucuronic acid.36
1-Octanol has been demonstrated to block the low-threshold
calcium channel in the IO and thalamus in vitro.34,37 The maximum
tolerated dose preclinically in harmaline mice after intraperitoneal
administration using the straight-wire test was 1,000 mg/kg.38 The
Food and Drug Administration (FDA) food additive safety profile on 1-
octanol lists lethal acute toxicity levels in rodents (LD50) ranging from
1,790 to 15,000 mg/kg.
1-Octanol: clinical trials
1-Octanol was first chosen for clinical trials due to its superior
efficacy and safety profile in animal model testing, and the fact that
1 mg/kg dosing was considered to be safe in humans, as defined by the
Council of Europe. 1-Octanol is approved as a food flavoring
substance by the FDA.
The first clinical trial in ET was conducted using a low dose of
1 mg/kg in 12 patients.39 A single oral dose of 1-octanol showed a
moderate effect in reducing tremor up to 90 min after administration,
measured by accelerometry, using a double-blind, placebo-controlled
design. 1-Octanol was well tolerated and safe at this dosage. Three
patients (two in the octanol group, one in the placebo group)
complained of headaches occurring after the completion of the study.
In all three patients, the headache lasted for less than 2 h and
responded to acetaminophen. No changes in vital signs or liver
function tests were detected. No signs of intoxication were observed.
The second protocol using 1-octanol was an open-label dose
escalation study to find the maximal tolerated oral dose of 1-octanol.40
Octanol doses were escalated up to 64 mg/kg without evidence of
intoxication, though subjects had a sensation of sedation at maximal
doses. Efficacy was found at all dosages, and a trend toward a dose
response was noted. Safety profiles showed no significant adverse
events, with some mild side effects. Two subjects had a self-limited
headache following drug administration, four subjects noted a taste
associated with the drug approximately 1 h after ingestion, four
subjects described a transient mild asthenia without signs of
intoxication, and two subjects had a prolonged feeling of lethargy at
64 mg/kg lasting for several hours. Single reports of nausea, dry
mouth, calcium oxalate crystals in the urine, and urinary tract
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infections were present, and in the case of the last two were likely
unrelated. No laboratory abnormalities or electrocardiogram (EKG)
changes were noted.40
The most recent 1-octanol protocol (clinicaltrials.gov ID:
NCT00102596) investigated the pharmacokinetic properties of two
different oral formulations of 1-octanol in 15 patients with ET.41 The
first formulation consisted of 1-octanol adsorbed to microcrystalline
cellulose and fine particle silica and encapsulated; the second
formulation consisted of a soft-gel capsule containing 1-octanol
embedded in soybean oil.41
This protocol was designed as a three-phase unblinded inpatient
study of adults with ET receiving weight-adjusted oral dosages of two
different formulations of 1-octanol in a crossover fashion. Phase 1 of
the study was designed to develop octanol and OA detection assays
using high-performance liquid chromatography. Five subjects in phase
1 received daily escalating dosages (1–64 mg/kg) of a single 1-octanol
formulation. In phase 2, 10 subjects received one of the two
formulations at 64 mg/kg during two inpatient days separated by
one washout-day. In phase 3, two patients received a high-dose
challenge of both formulations of 1-octanol (128 mg/kg).
Plasma concentrations of both 1-octanol and OA were detectable as
early as 5-min post dose. While OA concentrations showed a dose
response, 1-octanol remained at very low basal levels until the 64 mg/
kg dose. The OA plasma half-life was 73.6 min. In phase 3 of the
study, after the administration of a high dose of 1-octanol (128 mg/kg),
observed OA plasma levels followed a linear relation compared with
lower doses of 1-octanol. These findings suggested that 1-octanol is
rapidly converted to OA, which might then act as the active
metabolite. Efficacy was measured using objective digital tremor spiral
analysis.42 Spiral tremor measurements showed a 32% reduction in
tremor amplitudes at 90 min with significant tremor improvement up
to 180 min after administration. The safety profile of 1-octanol up to
128 mg/kg resembled prior studies with non-serious side effects being
mild and self-limiting. The most frequent adverse event was taste
change, which was reported by eight subjects (38%), followed by
headache, heartburn, and bloating (each five subjects, 24%). Nausea
and dry mouth were reported by four subjects (19%), and three
subjects reported constipation (14%). Two serious adverse events were
not related to the study drug. Again, no signs of intoxication were
noted at either dose level.
Octanoic acid
OA (synonym: caprylic acid) is a fatty acid with an eight-carbon
chain, which has been shown to inhibit gap junction permeability in
cultured rat astrocytes.43 Whether this observation is relevant to
explain a potential effect in ET remains uncertain, as it is not known
whether OA also blocks neuronal gap junctions. OA occurs naturally
in palm and coconut oils, as well as in human and bovine milk, and is
part of commercially available nutritional supplements (CaprinolH,
CaprylH). After absorption in the intestinal mucosa and entering the
portal venous system, the hepatic metabolism of OA involves
catabolism via b-oxidation to acetyl coenzyme A (CoA) with
subsequent entry into the Krebs cycle. Extrahepatic metabolism of
OA involves oxidation into CO2 within extrahepatic tissues.
44,45
The FDA has registered OA as a food additive and adjuvant of food
products, and assigned it ‘‘GRAS’’ (Generally Recognized as Safe)
status. Currently, OA is mainly used as a food and cosmetic additive as
well as an assessment method of gastric emptying (13C OA breath test).
The Council of Europe lists OA as a flavoring substance with an upper
limit of 50 mg/kg in food.46 Orally administered OA shows a
bioavailability of nearly 100%.47 In the rat, OA permeated the blood–
brain barrier, with 94% of peripherally injected OA being measurable
in the brain.48 To our knowledge, there are no data in the literature on
the elimination profile of OA from the CNS. In a study of acute oral
toxicity in rats, the LD50 was 10,080 mg/kg.
49
Octanoic acid: experience from human exposure
There is considerable data available on human exposure of OA. In
humans, according to a single-dose administration paradigm of
medium-chain fatty acids, a dietary consumption of up to 710 mg/
kg was considered safe.50 In a clinical trial including a control group of
healthy volunteers, a total dose of 3,600 mg OA was administered via
intraduodenal infusion, and no clinical side effects were reported.51
OA was furthermore studied as a component of a ketogenic diet as a
treatment strategy in children with intractable epilepsy, with a
duration of chronic administration for up to 2 years.52,53 An OA-
containing diet was administered on a daily basis as an emulsion with
the goal that 60% of the daily energy requirement was supplied by the
diet. Fifty children were included in the study, with 44 children
tolerating the diet. Reported side effects were diarrhea and abdominal
pain, which were alleviated by temporary dose reduction or intake
together with food. ‘‘Optimal’’ plasma levels of OA intended by the
authors was a target of 90 mg/mL peak plasma concentration (Cmax),
with the actual measured Cmax values ranging from 98.2 to 258.9 mg/
mL. Compared with the available pharmacokinetic data on OA in
essential tremor, these plasma levels were 75–200 times higher than
the Cmax we measured in the ET trial using 1-octanol. The dose vs.
plasma concentration relation was suggested to follow a linear
relationship.52
Further human data on OA stem from a study administering OA as
a formula to six premature infants. OA was administered orally in
doses ranging from 1.3 to 1.7 g/kg/d (mean 1.5¡0.2 g/kg/d) via a
medium-chain triglyceride diet over a period of at least 10 days. The
goal of this study was to investigate the metabolism of medium-chain
triglycerides in infants. The authors demonstrated the conversion of
OA into long-chain saturated fatty acids. The study did not mention
any adverse events.54 In a study of 23 cachectic patients, OA given
orally at a dose of 2.8 g daily over 2 weeks increased appetite scores,
body weight, and levels of total serum protein and albumin, with no
negative impacts on fasting glucose, total cholesterol, or triglycerides.
The aim of the study was to investigate the effect of OA on the
orexigenic hormone ghrelin, and demonstrated that OA led to an
increase in acyl ghrelin.55 High levels of OA were measured in patients
with a deficiency of medium-chain acyl-CoA dehydrogenase (OMIM
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#607008), an autosomal recessive inherited disorder of infancy and
early childhood leading to metabolic acidosis, hypoglycemia, lethargy,
coma, and if left unrecognized led to death in 25% of patients during
their first crisis.56,57 Regarding potential drug interactions, it has been
shown that high levels of OA can displace warfarin and non-steroidal
anti-inflammatory agents from albumin binding in human serum.58
Octanoic acid in ET: preclinical evidence
Because of OA’s presumed role as 1-octanol’s primary metabolite
and its biochemical properties, OA itself was hypothesized to act as a
potential therapeutic agent in ET. In the harmaline-induced mouse-
model of ET, OA showed a dose-dependent effect in reducing tremor
intensities, starting at 300 mg/kg administered intraperitoneally with a
maximum tolerated dose of 1,500 mg/kg. At therapeutic doses no
toxicity was observed, especially no signs of sedation or intoxication.38
Octanoic acid: first experience in ET
The aim of the first study of OA in ET was to examine the safety and
efficacy of a single oral OA dose in a double-blind, randomized,
placebo-controlled, crossover design (NCT00848172).59 Nineteen
patients with ethanol-responsive ET were included in the protocol. All
subjects received a dose that was defined as being safe according to
available toxicity data (4 mg/kg) and were monitored closely during the
total inpatient study phase of 3 days (day 0, baseline; days 1–2, active
study days). OA and placebo were administered on consecutive study
days in a randomized sequence. The primary outcome measure for this
study was the effect on tremor power of the dominant hand, 80 min
after administration of the study substance compared with placebo.
Tremor power was measured using accelerometry with loading to test
the central tremor component. Secondary outcome measures included
recordings of tremor power as measured by accelerometry at multiple
other time points up to 300 min after administration. The change in
tremor severity documented by digital spiral analysis, safety assessment
(laboratory testing, documentation of vital signs, adverse events
questionnaire, and intoxication scale), and pharmacokinetic sampling
acted as a further secondary outcome parameter.
Efficacy endpoints measured with tremor accelerometry did not
meet the primary endpoint (reduced tremor power of the dominant
hand 80 min after administration, compared with placebo). However,
secondary efficacy measures showed a significant benefit over placebo
at later time points, starting at 150 min. At the last observational time
point, 300 min, there was still a significant reduction in tremor power
compared with baseline.
Pharmacokinetik analysis of OA showed a tmax at 72.8 min, a
relatively large volume of distribution (389 L), and an elimination half-
life of 83.5 min. The elimination did not entirely follow first-order
kinetics, suggesting the presence of a second compartment. The mean
Cmax after administration of 4 mg/kg was 1,288.4 ng/mL, which is
close to the Cmax of OA that was measured after the administration of
4 mg/kg of 1-octanol.
Safety analysis showed that the dose was safe and well tolerated.
There were no serious adverse events related to OA, with non-serious
adverse effects being mild, self-limiting, and equally present after OA
and placebo. Two serious adverse events were classified as not related
to OA (food poisoning with isolated troponin I elevation after placebo,
and bleeding from the insertion site of a peripherally inserted central
venous catheter after premature removal of pressure dressing). There
were no significant abnormalities noted on vital signs, EKG, or
laboratory measures throughout the study.
Summary and outlook
With pharmacotherapy in ET often being limited by insufficient
efficacy, intolerable side effects, and potential drug interactions, novel
treatments for ET are strongly needed. While the ethanol effect in ET is
still not fully understood and currently under investigation, it is clear that
the majority of patients experience a clinically significant effect of tremor
reduction even after low doses of ethanol consumption, often exceeding the
effects of pharmacological treatments such as propranolol and primidone.
With the detailed mechanism of effect of ethanol in ET still to be
determined, promising preclinical data led to the further development
of long-chain alcohols as potential treatment agents in ET. It is
however important to point out that ethanol shows different (lower)
affinity to target structures than longer-chain alcohols such as 1-
octanol. It is therefore not necessarily the case that ethanol and 1-
octanol act via the same mechanism. Also, 1-octanol might act not via
one, but multiple mechanisms (i.e., blockage of gap junction, T-type
calcium channels, GABA-receptor interaction).
The fact that the 1-octanol and OA studies so far required
participants to exhibit a beneficial response to ethanol therefore stems
from a debatable assumption of similar pathways facilitating the effect. It
is however also important to point out that the current concept on the
proportion of ET patients responding beneficially to ethanol, or not, is
likely outdated, as these data stem from purely subjective reports.
Objective data from larger-scale populations are still pending, to
investigate whether differences in ethanol response can be objectively
delineated and whether therefore a concept of two separate ET
endophenotypes based on ethanol response can be sustained. However,
in the light of the current diagnostic uncertainty and significant
disagreement in the field on the ‘‘core’’ ET phenotype, a limitation to
objective ethanol responders might be justified for early stage clinical
trials to achieve a cohort exhibiting a more homogeneous phenotype.
With three clinical trials available on efficacy, safety, and
pharmacokinetic properties of 1-octanol, the main results can be
summarized as 1-octanol being safe and well tolerated in doses up to
128 mg/kg. The most common adverse event was mild and transient
dysgeusia, with patients reporting a distinct taste of orange peel, which
was to be expected as 1-octanol as natural flavoring substance is
present in orange peel. In terms of efficacy, all studies demonstrated a
significant treatment effect of 1-octanol, though it should be noted that
only the first, low-dose study was a double-blind, placebo-controlled
design. One major finding of the 1-octanol trials was the detection of
OA as an active metabolite with a significant plasma response after the
administration of 1-octanol. The feasibility of 1-octanol was further-
more questioned, not only because the distinct taste would make
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sufficient blinding challenging, but also because of the relatively large
volumes to be administered orally at doses of 64 and 128 mg/kg: even
with the formulation using the highest 1-octanol concentration (gel
capsule containing 800 mg 1-octanol), a patient weighing 78 kg who
took part in the highest dose group of 128 mg/kg had to swallow 12
capsules as a one-time dose.
OA itself showed an excellent safety and efficacy profile in
preclinical testing and during human exposure as a nutritional agent,
even at high doses and in vulnerable subjects such as preterm infants.
While OA was well tolerated in a pilot study using a low dose (4 mg/
kg), the primary efficacy outcome was not met, with OA not being
different from placebo in reducing tremor 80 min after administration.
However, the study design included several secondary efficacy
outcomes, which showed a significant effect on tremor at later time
points. The observation of a peak in plasma levels at 73 min being
dissociated from a clinical effect manifesting at 150 min and later, in
conjunction with an elimination profile compatible with a second
compartment, suggests that the second compartment is likely the CNS,
where the clinical effect is manifesting after distribution of the
compound across the blood–brain barrier, potentially explaining the
lag of a clinical efficacy peak following the plasma peak. While the
effect was evident using highly sensitive tremor accelerometry, other
methods better reflecting daily-life activities such as digital spiral
analysis were not different between OA and placebo. As this was a low-
dose study, it was assumed that the effect at 4 mg/kg was still small
and not yet translating into a clinically relevant benefit. Therefore, a
dose escalation study, with the goal of defining a maximum tolerated
dose with doses up to 128 mg/kg, was initiated (NCT01468948), with
the results at the time of this review still pending. Further studies are
needed on the effect of OA when administered continuously (e.g.,
twice daily, three times daily, etc.), on the further characterization of
OA’s pharmacokinetic profile at higher doses, and the optimization of
the drug’s formulation.
To conclude, despite its efficacy and safety, 1-octanol itself does not
seem a feasible candidate for further development due to the relatively
large volumes to be administered when formulated in capsules for oral
administration, as well the finding of OA as the active metabolite.
Although OA’s mechanism of action in ET is still unknown, the
therapeutic potential of OA in ET can be considered as significant, due
to promising preclinical and early-stage clinical trial data. However, a
clinically relevant effect translating into a reduced burden of tremor in
patients’ daily lives still remains to be demonstrated, and additional
phase 2 data on safety and efficacy in a long-term administration
setting are necessary, in order to keep OA moving forward towards
prime time.
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